Search
Search Results
-
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
CD38 is a transmembrane glycoprotein that functions both as a receptor and an ectoenzyme, playing key roles in the regulation of calcium signaling...
-
Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis
BackgroundDaratumumab and isatuximab are anti-CD38 monoclonal antibodies indicated for the treatment of multiple myeloma. These agents can increase...
-
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
BackgroundDaratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous...
-
A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India
The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at...
-
Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?
Monoclonal antibody (mAb) therapy is now considered a main component of cancer therapy in Australia. Although traditionally thought of as pure...
-
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy
When first introduced, rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, brought about an alternative therapeutic paradigm for primary...
-
Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy
Antibody–drug conjugates consist of a monoclonal antibody attached to a cytotoxic therapeutic molecule by a connector. This association allows a...
-
CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer
BackgroundCD38 has been observed expressing in activated T cells, while the features and functions of CD38+ T cells in human NSCLC are still unclear.
...
-
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy
With recent advances in myeloma therapy, patients can achieve long-term remissions, but eventually relapses will occur. Triple-class refractory...
-
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
BackgroundAntibody-mediated rejection (ABMR) is a cardinal cause of renal allograft loss. This rejection type, which may occur at any time after...
-
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
BackgroundAntibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a...
-
Translating B cell immunology to the treatment of antibody-mediated allograft rejection
Antibody-mediated rejection (AMR), including chronic AMR (cAMR), causes ~50% of kidney allograft losses each year. Despite attempts to develop...
-
The three pillars in treating antibody-mediated encephalitis
The rapid initiation of immunotherapy has a decisive impact on the course of the disease in patients with antibody-mediated encephalitis (AE). The...
-
Lineage switch of KMT2A-rearranged adult B-lineage acute lymphoblastic leukemia following bispecific T-cell engager and monoclonal antibody therapy
Adult B-lineage acute lymphoblastic leukemia (B-ALL) with t(4;11)(q21;q23) is very rare. It is characterized by mixed-lineage leukemia and has the...
-
Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
Multiple myeloma (MM) is still an incurable disorder despite improved antibody and cellular therapies against different MM antigens. Single targeted...
-
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It...
-
Teclistamab: First Approval
Teclistamab (TECVAYLI ® ), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and...
-
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
IntroductionCiltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor...
-
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody-drug conjugates (ADCs) are a new class of monoclonal antibodies with the characteritic to specifically target tumor cells and to deliver a...
